Evidence map›Paper›PMID 31684203›Full record

ReviewAntibodies (Basel, Switzerland)2019

Immunoglobulin for Treating Bacterial Infections: One More Mechanism of Action.

Teiji Sawa, Mao Kinoshita, Keita Inoue, Junya Ohara, Kiyoshi Moriyama

Open access · goldAbstract readReview
In one paragraph

Review in Antibodies (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Isolation of Fusobacterium nucleatum-Induced Host Exosomal sRNAs.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Antimicrobial Properties of Colostrum and Milk.Antibiotics (Basel, Switzerland) · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Teiji SawaDepartment of Anesthesiology, School of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. anesth@koto.kpu-m.ac.jp.
Mao KinoshitaDepartment of Anesthesiology, School of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. mao5615@koto.kpu-m.ac.jp.
Keita InoueDepartment of Anesthesiology, School of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. keitaino@koto.kpu-m.ac.jp.
Junya OharaDepartment of Anesthesiology, School of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. j-ohara@koto.kpu-m.ac.jp.
Kiyoshi MoriyamaDepartment of Anesthesiology, Kyorin University School of Medicine, Tokyo 181-8611, Japan. mokiyo@ks.kyorin-u.ac.jp.
Kyoto Prefectural University of Medicine · JPKyorin University · JP

Funding

Japan Society for the Promotion of Science 15H05008Japan Society for the Promotion of Science 18K16521Japan Society for the Promotion of Science 24390403Japan Society for the Promotion of Science 26670791
6 · The paper itself

Abstract

The mechanisms underlying the effects of immunoglobulins on bacterial infections are thought to involve bacterial cell lysis via complement activation, phagocytosis via bacterial opsonization, toxin neutralization, and antibody-dependent cell-mediated cytotoxicity. Nevertheless, recent advances in the study of the pathogenicity of Gram-negative bacteria have raised the possibility of an association between immunoglobulin and bacterial toxin secretion. Over time, new toxin secretion systems like the type III secretion system have been discovered in many pathogenic Gram-negative bacteria. With this system, the bacterial toxins are directly injected into the cytoplasm of the target cell through a special secretory apparatus without any exposure to the extracellular environment, and therefore with no opportunity for antibodies to neutralize the toxin. However, antibodies against the V-antigen, which is located on the needle-shaped tip of the bacterial secretion apparatus, can inhibit toxin translocation, thus raising the hope that the toxin may be susceptible to antibody targeting. Because multi-drug resistant bacteria are now prevalent, inhibiting this secretion mechanism is an attractive alternative or adjunctive therapy against lethal bacterial infections. Thus, it is not unreasonable to define the blocking effect of anti-V-antigen antibodies as the fifth mechanism for immunoglobulin action against bacterial infections.

Indexed as

immunoglobulinIVIGLcrVPcrVtranslocationtype III secretion systemtype III secretory toxinV-antigen

Identifiers

PMID31684203
PMCPMC6963986
OpenAlexW2987213625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.